Home
News
Create
Screeners
Insights
Rekvina Laboratories
34.
99
-0.10
(-0.28%)
Market Cap
₹21.04 Cr
PE Ratio
-89.97
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.28%
1M
-20.46%
6M
+394.21%
1Y
+394.21%
5Y
+825.66%
View Company Insights
Latest news about Rekvina Laboratories
Rekvina FY26 Net Loss ₹25.47 Lacs, Revenue ₹126.54 Lacs
4 hrs ago
Today
Rekvina Laboratories Limited reported a widened net loss of ₹25.47 lacs for FY26, compared to ₹13.71 lacs in the previous year, with revenue from operations reaching ₹126.54 lacs. For the quarter ended March 31, 2026, the net loss stood at ₹6.05 lacs on a revenue of ₹72.36 lacs. The Board approved the acquisition of Radiant Parenterals Limited for ₹4.63 crore and an increase in authorised share capital, subject to shareholder approvals.
Rekvina Laboratories Discloses Voting Results for EGM on Capital Restructuring
Apr 11, 2026
Rekvina Laboratories Claims Exemption from Annual Secretarial Compliance Report for FY26
Apr 07, 2026
Rekvina Laboratories Submits Q4FY26 Dematerialisation Compliance Certificate to BSE
Apr 06, 2026
Rekvina Laboratories Open Offer: Detailed Public Statement Published for 26% Stake Acquisition
Mar 25, 2026
More news about Rekvina Laboratories
18
Mar 26
Rekvina Laboratories Schedules EGM for April 10 to Approve Capital Restructuring
Rekvina Laboratories has formally notified shareholders of an extraordinary general meeting on April 10, 2026, to vote on increasing authorized share capital from ₹3.50 crore to ₹6 crore, acquiring 100% stake in Radiant Parenterals for ₹4.62 crore through share exchange, and issuing additional equity shares for cash consideration.
17
Mar 26
Rekvina Laboratories Discloses Open Offer Public Announcement to BSE
Rekvina Laboratories Limited has formally disclosed to BSE Limited the receipt of a public announcement for an open offer by three acquirers - Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The offer seeks to acquire 28,90,100 equity shares at ₹10 per share, representing 26% of expanded share capital with total consideration of ₹2,89,01,000. The transaction was triggered by a share exchange agreement for acquiring Radiant Parenterals Limited, managed by Vivro Financial Services under SEBI regulations.
Rekvina Laboratories
34.
99
-
0.
10
(-
0.
28
%)
1 Year Returns:
+394.21%
Industry Peers
Sun Pharmaceutical
1,891.30
(+
0.
59
%)
Divis Laboratories
6,858.00
(-
0.
51
%)
Torrent Pharmaceuticals
4,469.20
(+
0.
90
%)
Cipla
1,401.90
(+
0.
17
%)
Dr Reddys Laboratories
1,318.50
(-
0.
26
%)
Lupin
2,284.50
(-
0.
04
%)
Zydus Life Science
1,036.45
(-
0.
42
%)
Mankind Pharma
2,514.10
(-
2.
70
%)
Aurobindo Pharma
1,546.70
(+
1.
92
%)
Laurus Labs
1,351.00
(-
0.
74
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar